Chemical Injuries Research Center, Systems biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Research and Development Department, PersisGen Par Biopharma Accelerator, Tehran, Iran.
Adv Exp Med Biol. 2021;1321:81-96. doi: 10.1007/978-3-030-59261-5_7.
The new coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), turned into a pandemic affecting more than 200 countries. Due to the high rate of transmission and mortality, finding specific and effective treatment options for this infection is currently of urgent importance. Emerging technologies have created a promising platform for developing novel treatment options for various viral diseases such as the SARS-CoV-2 virus. Here, we have described potential novel therapeutic options based on the structure and pathophysiological mechanism of the SARS-CoV-2 virus, as well as the results of previous studies on similar viruses such as SARS and MERS. Many of these approaches can be used for controlling viral infection by reducing the viral damage or by increasing the potency of the host response. Owing to their high sensitivity, specificity, and reproducibility, siRNAs, aptamers, nanobodies, neutralizing antibodies, and different types of peptides can be used for interference with viral replication or for blocking internalization. Receptor agonists and interferon-inducing agents are also potential options to balance and enhance the innate immune response against SARS-CoV-2. Solid evidence on the efficacy and safety of such novel technologies is yet to be established although many well-designed clinical trials are underway to address these issues.
新型冠状病毒(SARS-CoV-2)已演变为一种影响 200 多个国家的大流行病。由于其高传播率和高死亡率,目前迫切需要找到针对这种感染的具体有效治疗方法。新兴技术为开发针对 SARS-CoV-2 等各种病毒疾病的新型治疗方法提供了一个有前途的平台。在这里,我们根据 SARS-CoV-2 病毒的结构和病理生理机制以及对 SARS 和 MERS 等类似病毒的先前研究结果,描述了一些潜在的新型治疗选择。其中许多方法可用于通过减少病毒损伤或增强宿主反应的效力来控制病毒感染。由于 siRNA、适体、纳米抗体、中和抗体和不同类型的肽具有高灵敏度、特异性和重现性,因此可用于干扰病毒复制或阻止内化。受体激动剂和干扰素诱导剂也是平衡和增强针对 SARS-CoV-2 的固有免疫反应的潜在选择。尽管正在进行许多精心设计的临床试验来解决这些问题,但这些新型技术的疗效和安全性的可靠证据尚未建立。